A 60 year old man with CA prostate with osteoblastic secondaries in pelvis and lumbar vertebra showed well differentiated Adenocarcinoma prostate on needle biopsy. First line of treatment is
**Core Concept**
The management of metastatic prostate cancer involves a multidisciplinary approach, considering the balance between controlling tumor growth, alleviating symptoms, and preserving quality of life. In patients with osteoblastic metastases, the primary goal is to control the growth of the tumor and prevent further skeletal complications.
**Why the Correct Answer is Right**
The first line of treatment for metastatic prostate cancer with osteoblastic secondaries is hormone therapy. This is because prostate cancer cells are androgen-dependent, meaning they require testosterone to grow. By reducing testosterone levels, hormone therapy can slow the growth of the tumor and alleviate symptoms. The most commonly used hormone therapy is **Luteinizing Hormone-Releasing Hormone (LHRH) agonists**, which work by initially stimulating the pituitary gland to release more luteinizing hormone, followed by a downregulation of LHRH receptors, leading to a decrease in testosterone production. This approach is particularly effective in patients with osteoblastic metastases, as it can help prevent further skeletal complications.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because chemotherapy is typically reserved for patients who have failed hormone therapy or have a high risk of progression.
**Option B:** This option is incorrect because radiation therapy is primarily used to alleviate symptoms in patients with localized or locally advanced disease, rather than as a first-line treatment for metastatic disease.
**Option C:** This option is incorrect because surgery is usually not indicated for metastatic prostate cancer, as it is often not feasible or effective in this setting.
**Clinical Pearl / High-Yield Fact**
It is essential to note that the choice of hormone therapy may depend on the patient's specific characteristics, such as the presence of hormone receptor status, and the presence of other comorbidities.
**Correct Answer:** C.